

Transcatheter Aortic Valve Replacement Selected Graphics

Medtronic

2020 Institutional Investor & Analyst Day

October 14, 2020



INVESTOR DAY 2020

Nina Goodheart

Senior Vice President and President, Structural Heart & Aortic



Medtronic is well positioned in rapidly growing TAVR market

Medtronic



**Global TAVR market
will continue to deliver
exceptional growth**

LOW-TEENS

Market CAGR

\$7B+

Market size FY25

Medtronic



Market leadership

#1

EMEA Share

+1%

US Share Gain
Q1 FY21 vs. Q4 FY20

Medtronic



Evolut™ is now the only valve indicated for Bicuspid Intermediate Risk and above in Europe.

Medtronic


Evolut™ PRO+ System

Industry-leading hemodynamic performance

Lowest delivery profile



Medtronic



Low risk approval driving paradigm shift in device selection criteria

Evolut™ demonstrates excellent clinical
outcomes in low risk patients

Medtronic



Procedural
success


Medtronic

A man and a woman are hiking on a rocky trail in a forest. The man is wearing a red and white plaid shirt and blue jeans, and the woman is wearing a blue zip-up hoodie and denim shorts. Both are using green trekking poles. The background is a dense forest with large trees and moss on the ground.

Lifetime management

Hemodynamics & Durability

Medtronic



Medtronic



INVESTOR DAY 2020

Jeffrey Popma, M.D.

Chief Medical Officer, Structural Heart, Coronary, Renal Denervation



Evolut demonstrates excellent clinical outcomes at ACC, TVT, EuroPCR conferences

The only transcatheter valve that shows

- Larger aortic valve areas
- Low gradients
- Sustained at 8 years
- Italian Registry

Medtronic



**Evolut demonstrates
excellent clinical
outcomes at ACC, TVT,
EuroPCR conferences**

The only transcatheter valve
that shows

- Low rates of Valve Thrombosis

Medtronic



Evolut demonstrates excellent clinical outcomes at ACC, TVT, EuroPCR conferences

The only transcatheter valve that shows

- Significantly less valve reinterventions
- At 8 years
- VIVID Registry

Medtronic




**Published in Journal of the
American Medical
Association of Cardiology**

**First to Report TAVR Outcomes
in Patients with Bicuspid Aortic
Valve**

- Low Gradients
- No Moderate PVL
- No Annular Rupture

Medtronic



Medtronic



Evolut™ TAVR: Global indications & clinical trials

The SMART Trial

Head-to-Head Comparing Valve performance

Medtronic Evolut PRO & PRO+ vs. Edwards Sapien 3 & Sapien 3 Ultra

Medtronic



Evolut™ TAVR: Global indications & clinical trials

Evolut™ EXPAND TAVR I
Feasibility Study

Next frontier for TAVR

Symptomatic moderate
and asymptomatic severe
aortic stenosis populations

Medtronic

Innovation-driven growth to achieve global TAVR leadership

TODAY



EVOLUT™ PRO+
SYSTEM

FUTURE PLATFORMS

EVOLUT™ FX


Improving
procedural
experience

NG EVOLUT™
ITERATION

Simplifying
post-TAVR
coronary access


NG EVOLUT™
TRANSFORMATION

Designing solutions for
patients who receive
multiple valves





Medtronic



Medtronic